Menopausal vasomotor symptoms (VMS), including hot flashes and night sweats, significantly impact quality of life, sleep, and daily functioning. While hormone therapy has long been the standard, safety concerns and contraindications have created a need for effective non-hormonal pharmacologic alternatives.

Emerging evidence suggests that neurokinin-3 receptor (NK3R) antagonism may offer a novel, targeted approach to managing VMS. By modulating hypothalamic thermoregulatory pathways implicated in VMS, this mechanism targets neurobiological processes associated with hot flashes. Clinical trials have demonstrated reductions in the frequency and severity of VMS, with improvements reported as early as the first week in some studies and sustained over time.

Patient-reported outcomes also suggest potential benefits in sleep, daily functioning, and overall quality of life. NK3R antagonists have been generally well tolerated in clinical trials, with headache and fatigue among the most commonly reported adverse events. Transient elevations in liver enzymes have been observed, and monitoring may be warranted in some patients.

How do you approach treatment selection for patients who are not candidates for hormone therapy? What role could targeted thermoregulatory pathways play in future menopause management?